Interestingly, in a cohort of 109 patients with colon cancer, the “inflammatory” variant NR1I2 rs10934498 (G > A) was identified, from a panel of NR1I2 variants, as one of the main determinants of Irinotecan pharmacokinetics [104]. This evidence concerns the gene NR1I2 and colonic neoplasm.